ASAkira Sakurada

Akira Sakurada

*This is an algorithmically generated author record based on publicly available information.

Akira Sakurada has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • EP08.02-10 Clinicopathological Analyses for Predicting Survival After Salvage Surgery for Initially Unresectable Lung Cancer

    by N. Oka, T. Hishida, K. Kaseda, Y. Oshiro, A. Sakurada, K. Sugino, H. Aoki, Y. Ishiguro, T. Imoto, Y. Okubo, et al.

  • An intronic single nucleotide polymorphism in the MUTYH gene is associated with increased risk for HCV-induced hepatocellular carcinoma

    by Akira Sakurada, Koji Miyanishi, Shingo Tanaka, Masanori Sato, Hiroki Sakamoto, Yutaka Kawano, Kohichi Takada, Yusaku Nakabeppu, Masayoshi Kobune, Junji Kato


  • Open Access

    High preoperative plasma vasohibin‐1 concentration predicts better prognosis in patients with non–small cell lung carcinoma

    by Tatsuaki Watanabe, Tomoko Hosaka, Kaori Ohmori‐Matsuda, Yasuhiro Suzuki, Hirotoshi Suzuki, Hiroshi Yabuki, Yasushi Matsuda, Masafumi Noda, Akira Sakurada, Yoshinori Okada, et al.

    Background and Aim: Vasohibin‐1 (VASH1) is an angiogenesis inhibitor synthesized and secreted by endothelial cells, whose expression is induced by angiogenic stimuli such as vascular endothelial growth factor. We have previously demonstrated that VASH1 is immunohistochemically evident in endothelial cells in the tumor microenvironment of patients with non–small cell lung cancer (NSCLC) and is positively correlated with that of vascular endothelial growth factor in cancer cells. Here, we determined the preoperative plasma concentration of VASH1 in patients with NSCLC and evaluated the association between the preoperative VASH1 levels and certain outcomes.Methods: We analyzed presurgical plasma VASH1 concentrations in a total of 79 lung cancer patients (51 males and 28 females; 34‐83 y of age; 46 adenocarcinomas, 27 squamous cell carcinomas, and 6 other types) who underwent lung resection. The impact of preoperative VASH1 level was analyzed using clinical characteristics and prognosis.Results: Plasma VASH1 concentration ranged from 34.1 to 1190.4 fmol/mL. We divided the patients into 3 groups according to plasma VASH1 level for this assessment: low VASH1 group (n = 26), medium VASH1 group (n = 27), and high VASH1 group (n = 26). The death and recurrence rates of the high, medium, and low VASH1 groups were 5.5, 16.2, and 12.7 per 100 person‐years, respectively. Multivariate adjusted hazard ratio of death and recurrence of the high VASH1 group was lower than that of the low VASH1 group (hazard ratio 0.42; 95% CI 0.17‐0.99).Conclusion: The present analysis suggests that high preoperative plasma VASH1 concentration is associated with better prognosis in patients with NSCLC. We propose preoperative VASH1 level as a biomarker for the prognosis of patients with non–small cell lung carcinoma.


  • Bone marrow mesenchymal stromal cells protect allograft lung transplants from acute rejection via the PD-L1/IL-17A axis

    by Naoya Ishibashi, Tatsuaki Watanabe, Masahiko Kanehira, Yui Watanabe, Yasushi Hoshikawa, Hirotsugu Notsuda, Masafumi Noda, Akira Sakurada, Shinya Ohkouchi, Takashi Kondo, et al.

    Using a rat model of allograft lung transplantation, we investigated the effectiveness of mesenchymal stromal cells (MSCs) as prophylactic and therapeutic agents against the acute rejection of lung grafts.


  • Primary tumor location as a prognostic and predictive factor in metastatic colorectal cancer (mCRC) treated with chemotherapy plus cetuximab: A retrospective analysis.

    by Tamotsu Sagawa, Kyoko Hamaguchi, Akira Sakurada, Fumito Tamura, Tsuyoshi Hayashi, Koshi Fujikawa, Yasuo Takahashi, Yasushi Sato

    711 Background: Left- and right-sided colon cancers are significantly different in epidemiologic, clinicopathological and molecular characteristics. However, the impact of primary tumor location in mCRC treated biological targeted agent in combination with chemotherapy is unclear. We therefore investigated the prognostic and predictive impact of primary tumor location in mCRC. Methods: Single-institution, retrospective, case-control study was reviewed. A total of 96 patients with mCRC were enrolled between January 2011 and December 2015. We evaluated the association between tumor location and survival parameters in patients with previously untreated mCRC receiving first-line chemotherapy plus cetuximab or bevacizumab. The impact of primary tumor location for cetuximab and bevacizumab groups was analyzed, respectively. Left-sided primary tumors were defined as tumors from rectum to splenic flexure, while right-sided primary tumors were defined as tumors from cecum to the distal part of the transverse colon. Results: 68 patients presented left-sided tumors and 28 patients right-sided primary tumors. In the cetuximab group, left-sided tumors were significantly superior to right-sided tumors in terms of the progression-free survival (PFS) and Overall survival (OS) (PFS, left vs right, 18.3 vs 6.8 M, p = 0.0415; OS, 50.6 vs10.5 M, p = 0.0004). Likewise, in the bevacizumab group, OS showed differences between the left- and right-sided tumors (PFS, left vs right, 11.6 vs 7.3 M, p = 0.1904; OS, 25.7 vs 16.2 M, p = 0.0389). In left-sided tumors, cetuximab group were significantly superior to bevacizumab group in terms of the OS (PFS, cetuximab vs bevacizumab, 18.0 vs 11.6 M, p = 0.1088; OS, 50.6 vs 25.7 m p = 0.0354). Conversely, in right-sided, the survival times showed no differences between cetuximab- and bevacizumab group (PFS, cetuximab vs bevacizumab, 6.8 vs 7.3 M, p = 0.7816; OS, 10.5 vs 16.2 M, p = 0.1088). Conclusions: Our study demonstrates that primary tumor location is an important prognostic factor in previously untreated mCRC. Furthermore, left-sided primary tumor location might be a strong predictor of PFS and OS in cetuximab therapy.


  • Open Access

    A case of curatively resected gastric wall implantation of pancreatic cancer caused by endoscopic ultrasound-guided fine-needle aspiration

    by Akira Sakurada, Tsuyoshi Hayashi, Michihiro Ono, Hirotoshi Ishiwatari, Jiro Ogino, Yasutoshi Kimura, Junji Kato

    An 87-year-old woman with a pancreatic mass was referred to our hospital for treatment. Contrast-enhanced computed tomography (CT) revealed a 25-mm-diameter mass with cystic changes in the body of the pancreas ([Fig. 1 a]). Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) was performed using a 22-gauge needle ([Fig. 1 b]), and cytohistological examination revealed a squamous cell carcinoma. Accordingly, distal pancreatectomy was performed, and the lesion was diagnosed as an adenosquamous carcinoma of the pancreas with T2N0M0 classification. The patient rejected adjuvant chemotherapy but consented to routine blood tests and contrast-enhanced CT every 3 months to monitor for recurrence. At 19 months after surgery, the tumor marker CA19-9 level had increased within the normal range. A contrast-enhanced CT showed a 20-mm-diameter mass with cystic changes and features similar to those of the resected pancreatic mass in the posterior stomach wall, despite the absence of other metastatic lesions ([Fig. 2 a]). A second EUS-FNA was performed ([Fig. 2 b]) and the lesion was identified as another squamous cell carcinoma. Positron emission tomography showed no other metastases ([Fig. 2 c]), and the patient underwent partial gastrectomy. The lesion was diagnosed definitely as a needle-track implantation caused by EUS-FNA, as it arose from the gastric wall subserosa ([Fig. 3 a]) and its histology was identical to that of the squamous cell carcinoma within the primary pancreatic carcinoma ([Fig. 3 b, c]). No recurrence was observed for 16 months. To our knowledge, this is the first report of a gastric wall metastasis of pancreatic cancer caused by EUS-FNA with pathological proof of needle-track implantation. Although such a mechanism of metastasis is rare [1] [2] [3] [4], it seems mandatory that implantation is detected before metastases occur in order to ensure radical cure. Therefore, planned examinations and cautious interpretation of blood tests and images may be essential, even following curative resection of early-stage pancreatic cancer. Endoscopy_UCTN_Code_CPL_1AL_2AD


  • Open Access

    Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma

    by Daisuke Inoue, Takashi Suzuki, Yoichiro Mitsuishi, Yasuhiro Miki, Satoshi Suzuki, Shunichi Sugawara, Mika Watanabe, Akira Sakurada, Chiaki Endo, Akira Uruno, et al.

    P62/SQSTM1 is a selective substrate of autophagy, and aberrant accumulation of p62 has been observed in various pathological conditions. To understand the roles p62 plays in non‐small‐cell lung cancer (NSCLC), we carried out immunohistochemical analyses of p62 expression in a cohort of patients with annotated clinicopathological data. As analyses of murine and human hepatocellular carcinomas suggested a correlation between p62 and Nrf2 accumulations, we also examined NRF2 expression in the same cohort. The expression of NRF2 and p62 was examined by immunohistochemical methods in 109 NSCLC cases, which included patients with adenocarcinoma (n = 72), squamous cell carcinoma (n = 31), and large cell carcinoma (n = 6). Accumulation of NRF2 and p62 was detected in 34% and 37% of NSCLC patients, respectively. The accumulations of p62 and NRF2 did not correlate with each other, but both were associated with worse lung cancer‐specific survival (P = 0.0003 for NRF2; P = 0.0130 for p62). NRF2 status had an impact on NSCLC prognosis irrespective of histology types, but p62 status did so particularly in adenocarcinoma (P = 0.037). Multivariate analysis indicated that positive immunoreactivities of NRF2 and p62 were both independent factors predicting worse lung cancer‐specific survival (P < 0.0001 for NRF2 and P = 0.04 for p62). This study revealed that both NRF2 and p62 are independent prognostic factors for NSCLC. The prognostic impact of p62 status was pronounced in adenocarcinoma patients, suggesting that molecular mechanisms underlying cancer evolution differ between adenocarcinoma and squamous cell carcinoma. (Cancer Sci 2012; 103: 760–766)


  • S1604-1-6 Tracking Actuator for Evaluation of DTM on Spin-Stand

    by Shigeki Mori, Akira Sakurada, Mamoru Hatano, Akihiro Naganawa, Yotsugi Shibuya, Goro Obinata